ATR and non-small cell lung carcinoma: That is, the acquisition of one copy of ATM/ATR pathogenic mutation in pre-cancerous cells might not be sufficient to drive NSCLC tumor formation, and it also requires aberrations in FA/HR to disrupt the DDR pathways, thus further elevating the mutational rate and increasing the chance to introduce other crucial oncogenic mutations (Additional file 1: Fig S9).